Switch theme
Sign up to access all valuation multiples
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
2020
159
Last FY Revenue n/a
LTM EBITDA -$261M
$13.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Summit Therapeutics has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$261M.
In the most recent fiscal year, Summit Therapeutics achieved revenue of n/a and an EBITDA of -$213M.
Summit Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Summit Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$261M | XXX | -$213M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$263M | XXX | -$226M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$255M | XXX | -$221M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Summit Therapeutics's stock price is $18.
Summit Therapeutics has current market cap of $13.5B, and EV of $13.2B.
See Summit Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $13.2B | $13.5B | XXX | XXX | XXX | XXX | $-0.35 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Summit Therapeutics has market cap of $13.5B and EV of $13.2B.
Summit Therapeutics's trades at n/a EV/Revenue multiple, and -62.0x EV/EBITDA.
Equity research analysts estimate Summit Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Summit Therapeutics has a P/E ratio of -53.1x.
See valuation multiples for Summit Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $13.5B | XXX | $13.5B | XXX | XXX | XXX |
| EV (current) | $13.2B | XXX | $13.2B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -50.5x | XXX | -62.0x | XXX | XXX | XXX |
| EV/EBIT | -50.1x | XXX | -58.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -53.1x | XXX | -61.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -92.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSummit Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.4M for the same period.
Summit Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Summit Therapeutics's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Summit Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 40% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Summit Therapeutics acquired XXX companies to date.
Last acquisition by Summit Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Summit Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Summit Therapeutics founded? | Summit Therapeutics was founded in 2020. |
| Where is Summit Therapeutics headquartered? | Summit Therapeutics is headquartered in United States of America. |
| How many employees does Summit Therapeutics have? | As of today, Summit Therapeutics has 159 employees. |
| Who is the CEO of Summit Therapeutics? | Summit Therapeutics's CEO is Dr. Mahkam Zanganeh. |
| Is Summit Therapeutics publicy listed? | Yes, Summit Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Summit Therapeutics? | Summit Therapeutics trades under SMMT ticker. |
| When did Summit Therapeutics go public? | Summit Therapeutics went public in 2015. |
| Who are competitors of Summit Therapeutics? | Similar companies to Summit Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Summit Therapeutics? | Summit Therapeutics's current market cap is $13.5B |
| Is Summit Therapeutics profitable? | Yes, Summit Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Summit Therapeutics? | Summit Therapeutics's last 12 months EBITDA is -$261M. |
| What is the current EV/EBITDA multiple of Summit Therapeutics? | Current EBITDA multiple of Summit Therapeutics is -50.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
